Litcius/Paper detail

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch, Amit Bar‐Or, Robert J. Fox, André Palma da Cunha Matta, Timothy J. Turner, Erik Wallström, Xinyan Zhang, Miroslav Mareš, Ф. А. Хабиров, Anthony Traboulsee, François Grand’Maison, François Jacques, Anthony Traboulsee, Michaela Týblová, Eva Meluzínová, Radek Ampapa, Martin Vališ, Pavel Hradilke, Miroslav Mareš, Pavel Štourač, Katrin Gross‐Paju, David Laplaud, Guillaume Mathey, Bernard M.J. Uitdehaag, Evgeny Evdoshenkoo, Е. В. Попова, Maria Zakharova, N. А. Totolyan, И. В. Литвиненко, Ф. А. Хабиров, С А Сиверцева, Viera Hančinová, Ema Kantorová, María Luisa Martínez Ginés, Xavier Montalbán, Sara Eichau Maduano, José Meca-Lallana, Lluís Ramió‐Torrentà, Tetyanna Nehrych, V.M. Pashkovskyy, Sergii Moskovko, O. I. Kalbus, Marta Khavunka, Volodymyr Pryshchepa, Alla Goloborodko, Daniel Wynn, William Honeycutt, Sibyl Wray, Brian Steingo, Christopher LaGanke, DeRen Huang, John M. Hemphill, Lawrence Goldstick, Derrick Robertson

2021The Lancet Neurology192 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMultiple sclerosisPlaceboCohortInternal medicineInterferon beta-1aPathologyImmunologyAlternative medicineInterferon betaMultiple Sclerosis Research StudiesChronic Lymphocytic Leukemia ResearchRheumatoid Arthritis Research and Therapies
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial | Litcius